New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)

.

Saved in:
Bibliographic Details
Main Author: Article Editorial
Format: Article
Language:English
Published: Столичная издательская компания 2016-09-01
Series:Рациональная фармакотерапия в кардиологии
Online Access:https://www.rpcardio.online/jour/article/view/1319
Tags: Add Tag
No Tags, Be the first to tag this record!